A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT05147805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05147805
  • EudraCT 2021-001528-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Denmark, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Serbia, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05147805. Randomized; double masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2025-03-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Treprostinil Palmitil
Intervention (Drug)
Placebo
Lead sponsor
Insmed Incorporated (class: industry)

Record details

Record id
cardio:ct-nct05147805
Content hash
75c167fc82c7a73abc2cc496503dc054f43c871fcca9582d03177e9895554884